ANXA5 and hematopoietic and lymphoid cell neoplasm: The [99mTc]hydrazinonicotinamide-annexin V ([99mTc]HYNIC-annexin V) has been used for assessment of therapeutic responses in many solid tumors and hematologic cancers (62).